losartan-potassium and Epidermolysis-Bullosa-Dystrophica

Epidermolysis bullosa (EB) is comprised of a group of hereditary mechanobullous disorders that are characterised by extremely fragile skin and mucous membranes. This results in blister formation and non-healing wounds. This case report describes the results of an innovative treatment of two large skin lesions in a newborn with dystrophic recessive EB (DEB) who experienced bacterial superinfections and progressive anaemisation. The lesions were treated with platelet gels derived from allogeneic cord blood (cord blood platelet gel, CBPGs). The skin lesions were clinically evaluated and treated with CBPG weekly until they completely healed. The first and second lesion required CBPG applications for 2 and 4 weeks, respectively. Both lesions were monitored weekly for 6 weeks after the last CBPG application, and no significant relapses were observed during the follow-up period. This case indicates that CBPG is an effective and safe therapeutic option for managing newborns with DEB, particularly as treatment and prevention of fluid loss and superinfection.

Topics: Anemia; Anti-Bacterial Agents; Bacterial Infections; Blood Platelets; Epidermolysis Bullosa Dystrophica; Erythropoietin; Female; Fetal Blood; Gels; Hemorrhage; Humans; Infant, Newborn; Superinfection

Topics: Anemia, Iron-Deficiency; Child; Epidermolysis Bullosa Dystrophica; Erythropoietin; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Humans; Male; Recombinant Proteins; Sucrose

Topics: Adult; Anemia; Blood Transfusion; Chronic Disease; Delayed-Action Preparations; Epidermolysis Bullosa Dystrophica; Erythropoietin; Female; Ferrous Compounds; Folic Acid; Hematinics; Humans; Recombinant Proteins